Biotech · Public company · Bedford, MA, US

Stoke Therapeutics, Inc.

Ticker STOK · SEC CIK 0001623526

Track this companyFree. Adds Stoke Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials32 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

Sham ComparatorPhase 3 · Dravet SyndromeClinicalTrials.gov · fetched Nov 12, 2026
zorevunersenPhase 3 · Dravet SyndromeClinicalTrials.gov · fetched Nov 12, 2026
STK-001 - Multiple Ascending DosesPhase 2 · Dravet SyndromeClinicalTrials.gov · fetched Nov 12, 2026
STK-001 - Single Ascending DosesPhase 2 · Dravet SyndromeClinicalTrials.gov · fetched Nov 12, 2026
zorevunersen (STK-001)Phase 2 · Dravet SyndromeClinicalTrials.gov · fetched Nov 12, 2026

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromePHASE3 · ACTIVE_NOT_RECRUITING · started Jun 4, 2025ClinicalTrials.gov NCT06872125 · fetched Nov 12, 2026
An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromePHASE2 · ACTIVE_NOT_RECRUITING · started Jan 20, 2021ClinicalTrials.gov NCT04740476 · fetched Nov 12, 2026
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromePHASE1_PHASE2 · COMPLETED · started Jun 29, 2020ClinicalTrials.gov NCT04442295 · fetched Nov 12, 2026